Toxicity management of angiogenesis inhibitors: resolution of expert panel

Toxicity management of angiogenesis inhibitors: resolution of expert panel

On 22 June 2017 in St. Petersburg the expert panel was held on the topic Management of toxicity of angiogenesis inhibitors, which discussed current issues of systemic therapy of advanced differentiated thyroid cancer resistant to radioactive iodine therapy, advanced kidney cancer and questions of ef...

Full description

Bibliographic Details
Main Authors:	Pavel O. Rumiantsev, Maria I. Volkova, Sergey O. Podvyaznikov, Ilya S. Romanov, Elena K. Shavarova, Eugenia A. Shatokhina
Format:	Article
Language:	Russian
Published:	Endocrinology Research Centre 2017-12-01
Series:	Эндокринная хирургия
Subjects:	well-differentiated thyroid cancer radiodiodine resistance renal cancer angiogenesis inhibitors lenvatinib
Online Access:	https://surg-endojournals.ru/serg/article/viewFile/9472/7052

Similar Items

Modern therapy of radioactive iodine-refractory differentiated thyroid cancer: resolution of the Expert Council
by: P O Rumyantsev, et al.
Published: (2016-09-01)

Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis
by: Jin Hong Lim, et al.
Published: (2020-10-01)

The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer
by: P O Rumyantsev
Published: (2015-06-01)

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
by: Priyanka C. Iyer, et al.
Published: (2018-07-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer
by: Su X, et al.
Published: (2020-11-01)

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
by: Costa R, et al.
Published: (2016-02-01)

New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
by: Kevin Zarrabi, et al.
Published: (2017-02-01)

LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA
by: I. S. Romanov, et al.
Published: (2017-06-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
by: Naoki Fukuda, et al.
Published: (2021-05-01)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
by: Soo Young Kim, et al.
Published: (2019-06-01)

Significant Amelioration of Tracheal Stenosis following Lenvatinib in a Patient Who Has Anaplastic Thyroid Carcinoma with Bronchomediastinal Infiltration: A Case Report
by: Takahiro Fukuhara, et al.
Published: (2017-02-01)

Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer
by: P. A. Isaev, et al.
Published: (2016-06-01)

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities
by: Loredana Lorusso, et al.
Published: (2021-03-01)

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis
by: Soo Young Kim, et al.
Published: (2020-09-01)

Molecular-targeted therapy for advanced anaplastic thyroid cancer combined with nutritional support
by: Yuka Maegawa, et al.
Published: (2019-02-01)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
by: Soo Young Kim, et al.
Published: (2018-10-01)

Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
by: Yoshitaka Furuto, et al.
Published: (2018-10-01)

Augmentation of lenvatinib efficacy by topical treatment of miR-634 ointment in anaplastic thyroid cancer
by: Masahiro Kishikawa, et al.
Published: (2021-07-01)

Correlation of malignant thyroid nodule ultrasound contrast parameters with angiogenesis and cell proliferation
by: Jing Wan, et al.
Published: (2017-05-01)

Case Report: Management of an Elderly Patient With Metastatic Radioiodine-Resistant Differentiated Thyroid Cancer in a Rural Community, Remote From Specialist Oncology Services
by: Rachael Wybrew, et al.
Published: (2021-02-01)

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
by: Keisuke Enomoto, et al.
Published: (2021-02-01)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
by: Yasuko Hyogo, et al.
Published: (2018-11-01)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
by: Lorusso L, et al.
Published: (2016-10-01)

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
by: Hirotetsu Takagi, et al.
Published: (2021-03-01)

Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration
by: Silvia Martina Ferrari, et al.
Published: (2018-12-01)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
by: Tiziana Feola, et al.
Published: (2021-07-01)

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01)

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
by: Nigel Fleeman, et al.
Published: (2019-12-01)

Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report
by: Masayuki Tori, et al.
Published: (2018-06-01)

Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer
by: Seok-Mo Kim, et al.
Published: (2020-02-01)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
by: Personeni N, et al.
Published: (2019-01-01)

Targeted therapy of advanced renal cell carcinoma
by: A. M. Popov
Published: (2017-06-01)

Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
by: Amit Mahipal, et al.
Published: (2019-07-01)

Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
by: Tella SH, et al.
Published: (2019-11-01)

New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
by: A. M. Mudunov
Published: (2015-06-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

<sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
by: Freba Ahmaddy, et al.
Published: (2021-01-01)

Cannot write session to /tmp/vufind_sessions/sess_ec59382t4bldhla1kk6fpd0ukj